Mt. Sinai School of Medicine Fully Executes Clinical Trial Agreement with APIRx Pharmaceuticals, BV

FRIDAY JANUARY 17, 2020–A clinical trial entitled “Tolerability of Canabidiol in Adolescents with Cannabinoid Use Disorders” has been now fully executed with Mt. Sinai School of Medicine in New York. The major achievement for APIRx promises a bright future ahead for the study of the current adolescent drug addiction crisis and the lack of effective treatment as well as the potential offered by CBD in APIRx’ proprietary delivery format.

Cannabis use is increasingly pervasive among adolescents today, even more common than cigarette smoking. Early exposure of cannabis has been known to cause developmental issues in adolescents because it is during active periods of brain development. With the deadly rise of drug addiction, more and more research is needed in the medicinal field for the potential use of cannabidiol, CBD, to help alleviate the cravings of drug use. APIRx is part of a large and rapidly growing market opportunity in worldwide cannabis application for medicinal usage, which is constantly being re-forecasted, driven by regulatory adoption at state and federal levels (in a number of countries). While certain companies have received cGMP certification for certain manufacturing processes, APIRx is the first company to offer API’s and finished goods based on an end-to-end cGMP process, starting with cGMP-produced Cannabis plant.

Both patients and physicians are increasingly looking to cannabidiol (CBD) as the non-psychoactive antidote to combat chronic pain and dramatically reduce the chance of addiction. Adolescents who begin using marijuana before age 18 are four to seven times more likely than adults to develop a marijuana use disorder.

APIRx was born out of the growing need for cannabinoid-based pharmaceutical solutions for wound healing, dermatological diseases, medication’ related osteonecrosis of the jaws (MRONJ), appetite control and a number of other indications. To date, only synthetically produced cannabinoids have received cGMP certification–but these are quite expensive and artificial. APIRx’s products are cGMP certified, based on 100% natural cannabis plant products–and much more affordable. We believe that the market is headed in the natural cGMP direction from a regulatory compliance and consumer demand perspectives.

For more information and updates about our research with Mt. Sinai School of Medicine and our clinical trial “Tolerability of Canabidiol in Adolescents with Cannabinoid Use Disorders” follow our news posts.